Table 2.
Type III tests of fixed effects from mixed-effects model.
| Effect | Num DF | F Value† | Probability |
|---|---|---|---|
| Main effects | |||
| Vaccination_Time (Time 2, Time 3 vs. Time 1)‡ |
2 | 4.33 | 0.0133 |
| Vaccine type (AstraZeneca vs. Pfizer) |
1 | 148.31 | <0.0001 |
| Age (30-39, 40-49, 50-74 vs.16-29) |
3 | 51.15 | <0.0001 |
| Sex (Female vs. Male) |
1 | 6.16 | 0.0131 |
| Days post-vaccination | 6 | 18.78 | <0.0001 |
| Interaction terms | |||
| Days × Vaccination_Time | 12 | 1.26 | 0.2380 |
| Days × Vaccine type | 6 | 7.24 | <0.0001 |
| Days × Age | 18 | 1.70 | 0.0319 |
| Days × sex | 6 | 1.03 | 0.4010 |
| Vaccination_Time × Vaccine type | 2 | 1.22 | 0.2945 |
| Vaccination_Time × Age | 6 | 0.71 | 0.6446 |
| Vaccination_Time × Sex | 2 | 0.44 | 0.6412 |
Details of the linear mixed modeling are: Time of vaccination (Time 1, 07:00-10:59; Time 2, 11:00-14:59; Time 3, 15:00-21:59), vaccine type (Pfizer mRNA or AstraZeneca Adenovirus), age groups (from Table 1A), sex, and days post-vaccination were treated as fixed factors. A B-spline transformation of days post-vaccination was used to model the non-linear pattern of anti-Spike antibody responses (log10 transformed) post vaccination.
Abbreviation: DF = Degrees of Freedom.
†
For all F tests the denominator DF was 3359.
‡
For each F test, the fixed effect referent is the last term shown, the F and P values are the Type III tests of overall fixed effects.